Vobarilizumab: Phase IIb data

Top-line data from a double-blind, international Phase IIb trial in 251 patients with moderately to severely active RA who were intolerant to methotrexate or for whom continued methotrexate treatment was inappropriate showed that 150 mg subcutaneous

Read the full 360 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE